People

Dr Sylvaine Guérit is identified by Neuvasq as Head of Preclinical Research in its March 25, 2025 conference announcement and its own October 2026 EURETINA update. She presents the company’s preclinical Wnt surrogate antibody and neurovascular-barrier research; this is a research leadership role, not evidence of clinical efficacy or an approved medicine.